MEK INHIBITOR TRAMETINIB IN HIGH GRADE OVARIAN CANCER PROLIFERATION

被引：0
|
作者：
Chesnokov, Mikhail [1 ]
Jamroze, Anmbreen [1 ]
Ha, Wootae [1 ]
Chefetz, Ilana [1 ]
机构：
[1] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GMM-019
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [31] IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
    Dongol, Samina
    Zhang, Qing
    Qiu, Chunping
    Sun, Chenggong
    Zhang, Zhiwei
    Wu, Huan
    Kong, Beihua
    ONCOLOGY LETTERS, 2020, 20 (02) : 1179 - 1192
  • [32] Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors
    Kulkarni, Anjali
    Cooke, Carly
    Fazelzad, Rouhi
    Fung-Kee-Fung, Michael
    May, Taymaa
    Zigras, Tiffany
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (01): : 11 - 16
  • [33] MEK inhibition for low-grade serous ovarian cancer: are we there yet?
    Scaranti, Mariana
    Mathias-Machado, Maria Cecilia
    Guo, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 155 - 156
  • [34] CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines.
    Hoenisch, Joshua
    Kim, Hannah
    Dawson, Amy
    Lam, Nicole
    Cheasley, Dane A.
    Gorringe, Kylie
    Campbell, Ian
    Huntsman, David G.
    DiMattia, Gabriel
    Kobel, Martin
    Fernandez, Marta Llaurado
    Carey, Mark S.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 91 - 91
  • [35] Preclinical efficacy of combined MEK and Src inhibition: MEK inhibitor reverses resistance to Src inhibitor therapy in ovarian cancer cells
    Simpkins, Fiona
    Azzam, Diana
    Slingerland, Joyce M.
    CLINICAL CANCER RESEARCH, 2013, 19
  • [36] MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
    Hew, Karina E.
    Miller, Philip C.
    El-Ashry, Dorraya
    Sun, Jun
    Besser, Alexandra H.
    Ince, Tan A.
    Gu, Mengnan
    Wei, Zhi
    Zhang, Gao
    Brafford, Patricia
    Gao, Wei
    Lu, Yiling
    Mills, Gordon B.
    Slingerland, Joyce M.
    Simpkins, Fiona
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 935 - 947
  • [37] Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer
    Bussies, Parker L.
    Schlumbrecht, Matthew
    ONCOLOGIST, 2020, 25 (07): : E1124 - E1126
  • [38] Trametinib, a MEK inhibitor, augments nab-paclitaxel based chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Monahan, Sheena
    Stefaniak, Alexis
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER RESEARCH, 2017, 77
  • [39] Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours
    Leonowens, Cathrine
    Pendry, Carolyn
    Bauman, John
    Young, Graeme C.
    Ho, May
    Henriquez, Frank
    Fang, Lei
    Morrison, Royce A.
    Orford, Keith
    Ouellet, Daniele
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (03) : 524 - 532
  • [40] Determining efficacy of combining the MEK inhibitor trametinib with vincristine identified by unbiased high throughput screening in RAS-mutated colorectal cancer cells
    Ghosh, Susmita
    Fan, Fan
    Roszik, Jason
    Powell, Reid
    Park, Yong
    Stephan, Clifford
    Ellis, Lee M.
    Bhattacharya, Rajat
    CANCER RESEARCH, 2022, 82 (12)
12345